Ishikawa Michiro, Namiki Atsushi, Kubota Tetsuya, Yajima Suguru, Fukazawa Masayuki, Moroi Masao, Sugi Kaoru
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo.
Intern Med. 2006;45(2):51-5. doi: 10.2169/internalmedicine.45.1476. Epub 2006 Feb 15.
The aim of this study was to assess the effects of hydrophilic pravastatin and lipophilic atorvastatin on glucose metabolism and lipid metabolism in non-diabetic patients with hypercholesterolemia.
Fasting plasma glucose (FPG), hemoglobin A(1c) (HbA(1c)), total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC), and triglyceride (TG) levels were determined before and after statin treatment.
A total of 44 nondiabetic patients (FPG < or =125 mg/mL; HbA(1c) <5.8%) undergoing treatment with either pravastatin (n=21) or atorvastatin (n=23) for hypercholesterolemia were investigated.
FPG level in the pravastatin but not atorvastatin group was significantly lowered after vs before treatment. Accordingly, the HbA(1c) level in the atorvastatin but not in the pravastatin group was significantly increased. As expected, both TC and LDL-C levels were significantly lowered in both groups. In particular, the TC level in the atorvastatin group was more remarkably and significantly improved than in the pravastatin group. On the other hand, the HDL-C level in the pravastatin group but not in the atorvastatin group was significantly increased after the administration period. The TG level was unaffected in both groups.
Pravastatin was suggested to act favorably, while atorvastatin adversely, regarding it's effects on glucose metabolism in nondiabetic hypercholesterolemic patients, although atorvastatin exerted more potent cholesterol-lowering effects compared with pravastatin.
本研究旨在评估亲水性普伐他汀和亲脂性阿托伐他汀对非糖尿病高胆固醇血症患者糖代谢和脂代谢的影响。
在他汀类药物治疗前后测定空腹血糖（FPG）、糖化血红蛋白A1c（HbA1c）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDLC）、高密度脂蛋白胆固醇（HDLC）和甘油三酯（TG）水平。
共调查了44例接受普伐他汀（n = 21）或阿托伐他汀（n = 23）治疗高胆固醇血症的非糖尿病患者（FPG≤125mg/mL；HbA1c＜5.8%）。
与治疗前相比，普伐他汀组的FPG水平显著降低，而阿托伐他汀组未降低。相应地，阿托伐他汀组的HbA1c水平显著升高，而普伐他汀组未升高。正如预期的那样，两组的TC和LDL-C水平均显著降低。特别是，阿托伐他汀组的TC水平比普伐他汀组有更显著的改善。另一方面，给药期后普伐他汀组的HDL-C水平显著升高，而阿托伐他汀组未升高。两组的TG水平均未受影响。
对于非糖尿病高胆固醇血症患者的糖代谢，普伐他汀显示出有利作用，而阿托伐他汀则显示出不利作用，尽管阿托伐他汀与普伐他汀相比具有更强的降胆固醇作用。
